Mark Talamonti, MD, of NorthShore University Health System, discusses the technical prerequisites for minimally invasive surgery in pancreatic cancers and the potential benefits to patients.
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses a range of topics, including tyrosine kinase inhibitors, immune therapies, targeted approaches, and DNA damage repair strategies.
Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).
Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.
Ignacio Melero, MD, PhD, of the University Clinic of Navarra, Centre of Applied Medical Research, discusses in Spanish study findings on nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (Abstract 226).
Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on nivolumab alone or in combination with ipilimumab in patients with DNA mismatch repair–deficient/microsatellite instability high metastatic colorectal cancer (Abstract 519).
